The company filed a material 8-K report with the SEC, so the model re-ran its full analysis. The rest of the picture is mixed, so the headline alone is not enough for a clear call.
Stocks › TRAX
First Tracks Biotherapeutics, Inc. (TRAX) stock analysis
BUY 39% confidence · analysed Oct 15, 2026
On Oct 15, 2026, our model rated First Tracks Biotherapeutics, Inc. (TRAX) BUY with 39% confidence at a price of $36.04. That means most of the technical, fundamental, money-flow and news signals point to upside.
Analysed price$36.04
Technical picture
MACD is above its signal line, a sign that short-term momentum is turning up.
The price is below both its 50-day and 200-day moving averages, the classic picture of a downtrend.
Volume is about normal (1.3x the 20-day average).
Fundamentals
The company reports a profit margin of 0.0%.
In its latest quarter it earned $-0.95 per share, which missed the $-0.80 analysts expected.
Wall Street's average rating is 1.2 on a 1 (strong buy) to 5 (sell) scale, roughly a "strong buy", with an average price target of $72.50.
The next earnings report is expected around Nov 5, 2026; prices often move sharply around earnings.
Trade plan from the model
The model's long / bullish plan uses an entry near $36.04, a target of $44.98 (+24.8%) and a stop-loss at $29.91 (-17.0%).
That is a reward-to-risk ratio of about 1.5 to 1: the potential gain is not much bigger than the loss, so the setup is marginal.
The plan has a time limit: reassess by Nov 4, 2026 whatever the price does.
Entry$36.04
Target$44.98
Stop-loss$29.91
Reassess byNov 4, 2026
Research notes
TRAX’s bull case centers on ANB033, whose Phase 1b Cohort 1 results showed statistically significant reductions in gluten-induced intestinal damage and symptoms, with no serious adverse events reported; analysts see substantial upside if the program advances toward late-stage development. The bear case is that TRAX remains a clinical-stage biotech with no meaningful revenue, ongoing losses, execution risk, and an elevated valuation after a sharp share-price rally. The major recent catalyst was the positive October 12 Phase 1b readout, followed by a roughly $200 million private placement announced October 15, which strengthens near-term funding but may raise dilution concerns. The next key test is Cohort 2 data, expected in the first quarter of 2027, which should clarify durability and commercial potential.
The model's one-paragraph read
Leans BUY — composite score +0.39 (BUY). Technicals: RSI n/a, MACD bullish, price below SMA50. Fundamentals: margin 0.0%. Financial results: last EPS surprise -18.7%, next earnings 2026-11-05. FinGPT news read: positive. Internet research: TRAX’s **bull case** centers on ANB033, whose Phase 1b Cohort 1 results showed statistically significant reductions in gluten-induced intestinal damage and symptoms, with no serious adverse events reported; analysts see substantial upside if the program advances toward late-stage development. The **bear case** is that TRAX remains a clinical-stage biotech with no meaningful revenue, ongoing losses, execution risk, and an elevated valuation after a sharp share-price rally. The major recent catalyst was the positive October 12 Phase 1b readout, followed by a roughly $200 million private placement announced October 15, which strengthens near-term funding but may raise dilution concerns. The next key test is Cohort 2 data, expected in the first quarter of 2027, which should clarify durability and commercial potential. Suggested levels: entry $36.04, target $44.98, stop-loss $29.91, exit by 2026-11-04 (exit before next earnings (2026-11-05) -- this signal doesn't price in that report).
Past ratings for TRAX
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 15, 2026 | BUY | 39% | $36.04 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on TRAX
Oct 15, 2026 · First Tracks Biotherapeutics, Inc. files an 8-K: material agreement
Frequently asked questions
Is TRAX a buy right now?
As of Oct 15, 2026, our automated model rates First Tracks Biotherapeutics, Inc. (TRAX) BUY with 39% confidence: most of the technical, fundamental, money-flow and news signals point to upside. This is a model output for education, not personal investment advice.
What is the price target for TRAX?
The model's most recent plan targets $44.98 with a stop-loss at $29.91, from an entry near $36.04.
When does First Tracks Biotherapeutics, Inc. report earnings next?
The next earnings report is expected around Nov 5, 2026.
What does a BUY rating mean?
A BUY rating means most of the technical, fundamental, money-flow and news signals point to upside.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.